Bio-Rad Laboratories (NYSE:BIO) Issues Quarterly Earnings Results, Beats Expectations By $0.87 EPS

Bio-Rad Laboratories (NYSE:BIO) released its quarterly earnings data on Tuesday. The medical research company reported $2.62 EPS for the quarter, beating the consensus estimate of $1.75 by $0.87, FiscalAI reports. The company had revenue of $651.00 million for the quarter, compared to analyst estimates of $623.99 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm’s revenue was down .1% compared to the same quarter last year. During the same period last year, the company posted $2.61 earnings per share.

Here are the key takeaways from Bio-Rad Laboratories’ conference call:

• Q2 revenue was essentially flat at approximately $651 million, while currency-neutral sales declined 1.9% year over year. Clinical diagnostics returned to modest growth, but life sciences fell 5.1% on a currency-neutral basis due to academic-market weakness and a difficult process-chromatography comparison.
• Digital PCR remained a key growth driver, with currency-neutral revenue up 6% and instrument sales increasing more than 20%. Management cited broad-based competitive wins, the Stilla portfolio, and expected future consumables pull-through as support for mid-single-digit near-term growth and potentially high-single-digit growth over time.
• Management reaffirmed a cautious 2026 outlook, forecasting currency-neutral revenue growth of -3% to +0.5% and noting approximately $4 million of second-half headwinds from China, continued life-science softness, order timing, Middle East volatility, and elevated logistics costs.
• Bio-Rad announced organizational and footprint changes expected to generate $30 million-$35 million in annualized net savings, with most savings realized by the end of 2027 and an estimated 40-50 basis points of incremental operating-margin expansion in 2027. The company also highlighted AI-enabled productivity gains and continued investment in innovation.
• The company is maintaining its strategic flexibility around its Sartorius stake, describing it as a valuable and monetizable asset, while continuing constructive discussions with Elliott Management. Bio-Rad repurchased approximately $32 million of shares in Q2 and had $206 million remaining under its buyback authorization as of June 30.

Bio-Rad Laboratories Trading Down 0.5%

NYSE:BIO opened at $332.87 on Wednesday. The stock has a market cap of $8.91 billion, a price-to-earnings ratio of 54.84 and a beta of 1.06. Bio-Rad Laboratories has a one year low of $236.73 and a one year high of $343.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. The business’s 50-day simple moving average is $301.02 and its 200 day simple moving average is $287.81.

Analysts Set New Price Targets

BIO has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Bio-Rad Laboratories in a research note on Monday. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price target on the stock. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Finally, Zacks Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $303.33.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in Bio-Rad Laboratories by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,077,072 shares of the medical research company’s stock valued at $326,344,000 after acquiring an additional 14,134 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Bio-Rad Laboratories by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock valued at $128,948,000 after purchasing an additional 7,754 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Bio-Rad Laboratories by 2,271.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 397,171 shares of the medical research company’s stock worth $111,363,000 after purchasing an additional 380,422 shares during the last quarter. Sei Investments Co. increased its holdings in Bio-Rad Laboratories by 6.4% in the third quarter. Sei Investments Co. now owns 282,469 shares of the medical research company’s stock valued at $79,199,000 after buying an additional 17,084 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. raised its stake in Bio-Rad Laboratories by 9.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 259,577 shares of the medical research company’s stock valued at $78,649,000 after buying an additional 21,674 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported second-quarter earnings of $2.62 per share, well above the $1.75–$2.34 analyst estimates cited in the reports. Revenue of $651 million also exceeded expectations of approximately $624 million, while operating cash flow reached $98.7 million. Bio-Rad Laboratories Beats Q2 Earnings Estimates
• Positive Sentiment: Gross profit improved modestly to $345.8 million, and cash and cash equivalents increased to approximately $517 million, supporting the company’s balance-sheet flexibility. Bio-Rad Laboratories Q2 2026 Earnings
• Neutral Sentiment: Management updated fiscal 2026 guidance, forecasting revenue of $2.5 billion to $2.6 billion. The range reaches the current consensus estimate at its high end but implies limited growth expectations. Bio-Rad Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue was essentially flat year over year, while operating profit declined to $72.6 million. The muted top-line performance may raise concerns about demand and growth across Bio-Rad’s laboratory and life-science businesses. Bio-Rad Laboratories to Cut Jobs, Close Facilities
• Negative Sentiment: The company plans to cut jobs and close facilities, signaling continued cost pressure and potentially higher restructuring costs. Although the actions could produce longer-term savings, investors may initially view them as evidence of weaker operating conditions.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.